Trump, FDA and Hims & Hers

Johns Hopkins Marty Makary, Trump’s choice for FDA, a ‘brilliant surgeon’ with some ‘worrisome’ views
Maryland scholars on Monday alternately described President-elect Donald Trump’s pick to lead the U.S. Food and Drug Administration — Dr. Marty Makary, a Johns Hopkins researcher, surgeon and author — as a “courageous leader” and a “reasonable choice,” who nevertheless espouses some “worrisome” views.
Hims & Hers Shares Jump as Trump FDA Pick Seen as Major Ally
Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.
Hims & Hers jumps after Trump nominates Dr. Marty Makary for FDA
Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns
Who is Dr. Marty Makary, Trump’s pick to head the FDA?
The nominee, a surgeon at Johns Hopkins, has criticized the use of pesticides on food and the industry turning against “natural fat.”
Johns Hopkins surgeon and COVID contrarian Marty Makary selected to lead Trump’s FDA
President-elect Trump has picked Marty Makary, a Johns Hopkins’s surgeon who has espoused contrarian views about the COVID-19 pandemic, to lead the Federal Drug Administration. Makary
Trump picks Dr. Marty Makary as Food and Drug Administration commissioner
President-elect Trump announced on Friday that he is nominating Dr. Marty Makary, a Johns Hopkins School of Medicine professor, to head the Food and Drug Administration.
Trump picks Marty Makary to lead FDA, Dave Weldon to run CDC
Makary and Weldon, who have criticized the agencies they may soon run, were joined by Janette Nesheiwat, Trump’s pick to be surgeon general.
Healthy Returns: Trump's FDA pick Makary may be a relief for biotech and pharma, analysts say
Trump’s FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.
Hunterbrook goes long Hims & Hers after short position in June
After going short the stock in June based on Hunterbrook Media’s reporting, Hunterbrook Capital said today it is long Hims & Hers Health.
Hims & Hers surges: Analysts say it's well-positioned under Trump
Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald ...
STAT3d
‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
STAT reporters reached out to key figures in biotech, pharma, and medical devices to find out what they think about President ...
Becker's Hospital Review16h
The telehealth background of Trump's FDA pick: 6 notes
Mr. Trump nominated Marty Makary, MD, on Nov. 22 to head the FDA ... Shares of virtual care company Hims & Hers spiked after the news that a telehealth ally could be running the FDA, Bloomberg ...